Qiyuan Biological
Commited to developing of innovative drugs
About Qiyuan Biological
Enitiate Bio is a biotechnology company focused on developing innovative treatments for dermatological conditions, specifically atopic dermatitis. The company operates in the pharmaceutical and healthcare market, targeting both healthy subjects and patients with mild to severe atopic dermatitis. Enitiate Bio's business model revolves around the research, development, and clinical testing of novel therapeutic solutions. The company generates revenue through the successful development and commercialization of its proprietary drugs. Enitiate Bio is currently conducting Phase I and Phase II clinical trials for its QY211 gel and QY201 tablets, aiming to establish safety and efficacy in treating atopic dermatitis. These trials are being conducted in collaboration with leading medical institutions such as Huashan Hospital of Fudan University. By focusing on innovative dermatology solutions, Enitiate Bio aims to address unmet medical needs and improve patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 20.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Sep 2025 | $28M | $110M | ZSCO · Highlight Capital · Hangzhoushi Shiye Touzi Jituan Youxian Gongsi | ↗ |
| SERIES A✓Equity / VC | Aug 2022 | $14M | $55M | Taikun Fund · Hangzhou Jintou Industrial Fund · Jijie Investment · Linping SDIC | ↗ |
Growth signals
Latest recorded traffic for Qiyuan Biological is 810 monthly website visits, up 131.4% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Qiyuan Biological in its local ecosystem
The Qiyuan Biological office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
- TFTaikun Fund
- HFHangzhou Jintou Industrial Fund
- JIJijie Investment
- LSLinping SDIC
ZSCO
Highlight Capital- HGHangzhoushi Shiye Touzi Jituan Youxian Gongsi
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Qiyuan Biological on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Qiyuan Biological’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








